Bedside Snapshot
- Normal Result
- ABO and RhD typed (O, A, B or AB; positive or negative)
Antibody screen: negative - Significant Result
- Positive antibody screen or an unresolved ABO/RhD discrepancy: blood bank must identify the antibody or resolve the type first
- Positive Suggests
- Alloantibody from prior transfusion or pregnancy; autoantibody or drug-dependent antibody if the DAT is positive
- Negative Does Not Exclude
- Antibodies below the test's detection; an ABO or identity error. A fresh, correctly labeled sample is still needed for each transfusion
- Act Now If
- Bleeding or shock with delay that could be fatal: draw the sample, call the blood bank, start uncrossmatched group O per protocol
- Watch Out For
- A wrong-patient or mislabeled sample or unit: ABO errors cause the most severe acute reactions. Check identifiers at the bedside
Reference & Critical Ranges
Lab-specific ranges: The transfusion service (blood bank) reads blood group and antibody results. Terms and sample rules differ by laboratory. Use your facility's result and policy.
Reference ranges
| Population | Conventional | SI | Notes |
|---|---|---|---|
| Adult, ABO group | O, A, B or AB | Not applicable (no SI unit) | Typed on the patient sample by forward and reverse testing; both must agree. |
| Adult, RhD | Positive or negative | Not applicable | Frequency varies with ancestry. RhD-negative patients can form anti-D after exposure to RhD-positive red cells. |
| Adult, antibody screen | Negative | Not applicable | A negative screen means no antibody was detected by the test used; it does not exclude low-level antibodies. |
| Pregnancy | Same as adult | Not applicable | Antibody screening is part of prenatal care. Rh immune globulin is covered on the RhIG page. |
| Children | Same as adult | Not applicable | Same ABO and RhD rules. Policy for RhD-type of emergency products in girls and boys differs between centers. |
| Neonate (0–28 d) | Maternal antibodies may be detected | Not applicable | Maternal IgG can give a positive antibody screen or DAT in the infant. The blood bank interprets this result. |
Severity & critical values
| Result grade | Typical finding | Meaning |
|---|---|---|
| Negative | Screen negative; ABO and RhD typed | ABO and RhD typed, no clinically relevant antibody detected. Compatible red cells can be crossmatched or electronically matched per policy. |
| Significant | Antibody detected, identified or not yet identified | Antibody detected (identified or not yet identified). Antigen-negative red cells are needed, and preparation takes longer. |
| Positive DAT or warm autoantibody | DAT positive; screen may be weak or negative | Autoantibody or drug-dependent antibody can mask an alloantibody. Blood bank work-up takes longer and matching is less certain. |
| Critical | Unresolved discrepancy, or positive screen with urgent need | ABO or RhD discrepancy that is not resolved, or a positive screen in a patient who needs red cells now. Call the blood bank; use uncrossmatched group O only per protocol. |
Critical values: No number sets off the alarm here. An unresolved ABO or RhD discrepancy is critical. So is a positive antibody screen in a patient who needs red cells now. Call the blood bank and follow the emergency transfusion protocol.
Causes of Abnormal Results
Positive antibody screen
| Cause | Bedside clue |
|---|---|
| Alloantibody after transfusion | Recent transfusion or many prior transfusions, for example in sickle cell disease or other chronic transfusion. Immune response to donor red-cell antigens. |
| Alloantibody after pregnancy | Pregnant, or recently delivered or miscarried. RhD-negative mother with an RhD-positive fetus is the classic setting. |
| Warm autoantibody | Positive DAT with a screen that may not identify a single antibody. Look for hemolysis: low hemoglobin, jaundice, dark urine, raised LDH. |
| Drug-induced antibody | New drug exposure before the test. Some antibiotics and other drugs can cause immune hemolysis with a positive DAT, and occasionally a positive screen. Give the blood bank the full medication list. |
| Passive antibody | Recent immune globulin (IVIG) or Rh immune globulin, which carries donor antibody into the patient. |
| Cold agglutinin | IgM antibody reacting at room temperature or colder. Often not clinically significant at 37 °C, but it can complicate typing. |
Positive screen in an emergency: A positive screen slows the transfusion down. It does not stop it. Identify the antibody, select antigen-negative units, and keep the emergency pathway open while the blood bank works.
False positive vs true positive
- Probable false positive: Think reagent or technique error, a hemolyzed or lipemic sample, or cold agglutinin activity at the test temperature. A repeat test or a fresh sample often settles the question.
- Probable true positive: The reaction repeats on retest, and the panel cells show a pattern that fits one or more antibodies.
- Clinically significant or not: Plenty of detected antibodies do not matter clinically. The blood bank decides. It weighs the antigen, the antibody strength and the patient's history.
Discrepant ABO typing (forward vs reverse)
Common causes include a newborn or a hypogammaglobulinemic patient. The reverse reaction comes out weak there. A cold agglutinin or a passively acquired antibody, such as one from transfused plasma, gives an unexpected reverse reaction. An acquired B antigen in a group A patient means the typing no longer matches the historic group. Recent donor red cells cause a mixed-field result on forward typing instead.
Don't settle a discrepancy at the bedside by picking a group. That is the blood bank's problem to solve. Hand them the full history and the order of events.
Interpretation & Bedside Approach
Step-by-step approach
- Is the sample right? Confirm two identifiers, date and time on the tube at the bedside. Reject a clotted, hemolyzed or unlabeled sample, and redraw when the blood bank asks. Contamination with infusion fluid can change results.
- How urgent is the need for blood? Active bleeding, shock or symptomatic anemia moves the patient onto the emergency pathway. Start uncrossmatched group O only when delay could be fatal, per protocol.
- What is the transfusion and pregnancy history? Recent transfusion, pregnancy or chronic transfusion push antibody risk up. A screen that was positive before means this patient needs antigen-negative red cells. Those can take longer to find.
- Is the product compatible? Match the unit tag to the patient's identifiers and ABO group. Use the ABO table below. Where RhD-negative red cells are available, a female of childbearing potential should get them, per policy.
- What does the screen show? Classify the result as negative, positive with an identified antibody, positive DAT, or ABO or RhD discrepancy. Use the decision table below.
- Escalate or dispose: Call the blood bank with the result and the clinical urgency, transfuse per the crossmatch or emergency protocol, watch for reactions, and check for a delayed hemolytic reaction if the patient later becomes unwell.
ABO compatibility for transfusion
| Recipient group | Red cells that are ABO-compatible | Plasma that is ABO-compatible |
|---|---|---|
| O | O only | O, A, B or AB |
| A | A or O | A or AB |
| B | B or O | B or AB |
| AB | AB, A, B or O | AB only |
Every component that contains red cells has to match the antibodies in the recipient's plasma (AABB Circular of Information). Plasma and platelet rules are different. They sit on the blood products page.
Decision table
| Pattern | Suggests |
|---|---|
| Negative screen, ABO and RhD confirmed | Routine compatible red cells, crossmatched or electronically matched per laboratory policy. Electronic or immediate-spin crossmatch needs a negative current screen and no history of clinically significant antibody. |
| Positive screen, antibody identified | Antigen-negative units with an antiglobulin (AHG) crossmatch are needed. Expect a longer lead time; plan with the blood bank. |
| Positive DAT with weak or negative screen | Autoantibody or drug-dependent antibody, which can hide an alloantibody. Blood bank work-up may take longer. |
| ABO or RhD discrepancy | Blood bank resolves before crossmatched red cells. Uncrossmatched group O only when delay is life-threatening. |
| Falling hemoglobin or fever after transfusion, positive DAT | Possible delayed hemolytic transfusion reaction. Notify the blood bank and evaluate; see Timing & Kinetics. |
Identity check before every unit: A negative screen does not make a mismatched unit safe. At the bedside, check the patient's identifiers against the unit tag before you hang each product.
Management Priorities
Emergency: hemorrhage before typing is complete
- Draw the sample first: Get the type and screen from the first IV or IO before any blood goes in. Label the tube at the bedside: two identifiers, date and time. Draw from a site without an infusion where possible. An IO sample can pick up marrow, so follow local protocol and tell the blood bank where it came from.
- Call the blood bank: Open with the emergency. Then the patient's age, sex, and whether she is a female of childbearing potential.
- Start the bridge if delay would be fatal: Uncrossmatched group O red cells, per protocol. For a female of childbearing potential, RhD-negative units if they are stocked. Don't hold back RhD-positive units from someone who needs blood and has no RhD-negative units on hand.
- Switch to matched blood: Once results come back, switch to crossmatched or type-specific products. Tell the blood bank about every unit you give.
Blood products
| Product | Use | Notes |
|---|---|---|
| Uncrossmatched group O red cells | Life-threatening bleeding before typing is complete | Use only per blood bank policy. One unit raises hemoglobin by about 1 g/dL in an average adult; a smaller rise suggests ongoing loss. See blood products. |
| Group O whole blood or low-titer group O whole blood | Systems that stock it, as early resuscitation before the recipient group is known | Titer cutoffs are set by facility policy; there is no safe titer. Observational data in civilian trauma favor it over component therapy. See whole blood. |
| Type-specific crossmatched red cells | Default once compatibility is confirmed | Requires ABO, RhD and an antibody screen that match the unit tag. |
| Plasma, platelets and red cells in a protocol ratio | Massive transfusion protocol | Given per protocol; the ratio and calcium replacement are protocol-set. See blood products. |
| Rh immune globulin (RhIG) | Rh-negative patient exposed to RhD-positive blood, or a pregnant or postpartum patient with bleeding | Decision by the blood bank and obstetric team. See RhIG. |
| RhD-positive red cells for an RhD-negative female of childbearing potential | Only when RhD-negative units are not available and transfusion is needed | Do not withhold life-saving blood. Reported D-alloimmunization after trauma transfusion is about 8–43%; the blood bank arranges antibody surveillance and RhIG where indicated. See RhIG. |
| Tranexamic acid | Bleeding, given alongside products | Not a substitute for blood products. See tranexamic acid. |
Definitive care & disposition
- Positive screen: The blood bank identifies the antibody and lines up antigen-negative units. Plan timing with them. If that capacity is missing locally, consider transfer to a center that has it.
- Massive transfusion: The blood bank, ICU and transport teams all run the protocol. Track ionized calcium. It drops during rapid, large-volume citrated transfusion.
- Chronic transfusion (for example, sickle cell disease): Matching Rh and Kell ahead of time may cut alloimmunization, per transfusion medicine advice.
- Suspected delayed hemolytic reaction: Notify the blood bank, repeat the DAT, check hemoglobin, LDH and bilirubin, and consult transfusion medicine for a severe reaction.
Doses are typical references. Follow local protocols, medical direction and institutional policy.
Field & Transport Considerations
Point-of-care testing
In most systems, blood grouping and antibody screening happen in the lab. Field or point-of-care typing devices, where a service runs them, follow their own protocol. They do not replace the blood bank's compatibility testing. Prehospital teams do not pick a blood group in the field.
Before and during interfacility transport
- Sample: Obtain the sample before blood is given, if the protocol allows. Send it with the patient, labeled with two identifiers, date and time.
- Products: Keep unit tags with the patient and verify identifiers at each handoff. Carry products in the cooler or storage the product label requires.
- Receiving hospital: Ask whether the receiving blood bank needs a new sample. Each facility sets its own rules for accepting one.
- En route reactions: Fever, rash, dyspnea, hypotension or dark urine during a transfusion means the unit stops. Keep the line open with saline per protocol, and call the receiving team.
Timing & Kinetics
| Parameter | Value | Clinical implication |
|---|---|---|
| Sample validity | AABB Standards require a sample within 3 days of the planned transfusion for a patient transfused or pregnant in the prior 3 months, or with an uncertain history; many hospitals apply the 3-day window to every patient. Local policy sets any longer window | An expired sample blocks crossmatched blood. Ask early if the patient may need blood later. |
| Immediate hemolytic reaction | During or soon after an incompatible transfusion | Fever, chest or flank pain, hypotension and hemoglobinuria; stop the unit and call the blood bank. |
| Antibody appearance after exposure | Days to weeks; the timing varies by antigen and patient | A screen that was negative can become positive later. Retest when a new exposure occurs. |
| Delayed hemolytic transfusion reaction | Usually days to weeks after transfusion; can be later | Unexplained fever, a positive DAT and a falling hemoglobin. Most are benign, but evaluate the cause. |
Special Populations
| Population | What changes | Clinical implication |
|---|---|---|
| Neonates & infants | Maternal antibodies can appear on infant testing; reverse typing is often weak or absent | Do not assume a positive infant screen is the infant's own antibody. The blood bank interprets it, may rely on forward typing and the maternal antibody history, and selects products. |
| Children & adolescents | Same ABO and RhD rules; emergency RhD-type differs by center. In a 2021 US pediatric trauma survey, 92.7% of centers used RhD-negative red cells for girls up to 18 years and 54.5% for boys | Ask the blood bank which RhD-type will be issued for a girl or boy, and document the choice. |
| Pregnancy | Alloimmunization can harm a future fetus | RhD-negative pregnant patients need antibody screening and RhIG per obstetric protocol. From 20 weeks, bleeding or trauma needs fetomaternal hemorrhage quantitation and RhIG within 72 hours. See the RhIG page. |
| Older adults | No clinically meaningful difference in the test itself | Prior transfusion history is common and raises the chance of an existing antibody. |
Interfering Factors & Pitfalls
Collection & handling
| Factor | Effect | Why | Avoid / fix |
|---|---|---|---|
| Mislabeled or unlabeled tube | Wrong-patient result; ABO error | Identity cannot be confirmed | Label at the bedside with two identifiers, date and time; reject unlabeled tubes |
| Clotted or hemolyzed sample | Test failure or false reaction | Clot or lysed cells interfere with the reaction | Redraw; tell the blood bank |
| Contamination with infusion fluid | Unreliable result | Dilution or foreign cells alter the sample | Draw from a site without an infusion where possible; if not, stop the infusion per blood bank policy |
| Expired sample | No crossmatch possible | Antibody status may have changed | New sample per policy |
Medications & supplements
| Factor | Effect | Why | Avoid / fix |
|---|---|---|---|
| Anti-CD38 monoclonal antibody (for example, daratumumab) | False + antibody screen and crossmatch | The drug binds red-cell antigens used in testing | Tell the blood bank; special testing is needed |
| Immune globulin (IVIG) | False + screen possible | Passive donor antibody in the patient's plasma | Give the blood bank the date and product |
Physiologic & biologic
| Factor | Effect | Why | Avoid / fix |
|---|---|---|---|
| Warm autoantibody | False + or masked alloantibody | Antibody against the patient's own red cells | Blood bank adsorption or other specialized testing |
| Cold agglutinin | False + or confusing typing | Red cells clump at room temperature | Tell the blood bank when collecting; do not cool the tube. The laboratory sets storage, often warm (about 37 °C), and may use a pre-warmed technique |
| Recent transfusion | Mixed-field ABO typing | Donor cells circulate with the patient's own | Give transfusion times to the blood bank |
Common misinterpretations
- "A negative screen means any blood is safe": It does not take the place of the crossmatch or compatibility test. An ABO error can still happen.
- "A positive screen means no blood": It means you need antigen-negative units. That takes time, but it is usually possible.
- "Group O red cells are safe for everyone": They are the emergency choice for red cells only. Plasma and platelet rules are different.
ABO errors: Wrong-patient samples, mislabeled tubes and unit mix-ups cause the most severe acute hemolytic reactions. Confirm identifiers at the bedside before every unit.
Physiology & Test Basics
What it measures
Type and screen is the lab work done before any transfusion: ABO group, RhD type and an antibody screen on the patient's sample. Next comes a crossmatch, which tests the patient's plasma against one specific unit. This page covers blood compatibility. It does not cover the hemoglobin or CBC values that decide whether to transfuse.
Physiology & regulation
- ABO antigens: Red cells carry A, B or both, or neither (group O). The antibodies form without any known exposure. So the patient's plasma reacts with the antigen they lack.
- RhD antigen: RhD-positive or RhD-negative. Exposure to RhD-positive red cells can prompt an RhD-negative patient to make anti-D.
- Alloantibodies: They form after foreign red-cell antigens get in, through pregnancy or transfusion. They can cause delayed hemolysis.
- Screen cells: The lab tests the patient's plasma against group O reagent cells that carry common antigens. That is how unexpected antibodies show up.
How it is measured
Collect a whole-blood sample in the tube type the blood bank specifies, often a lavender (EDTA) tube. Label it at the bedside with two identifiers, date and time. The screen runs typing reagents and an antiglobulin test (IAT), by gel or by tube. How long it takes depends on the lab, and on how many antibodies need identifying.
Type and screen vs crossmatch: Type and screen is ABO/RhD typing plus the antibody screen. A crossmatch adds compatibility testing against a specific unit. Electronic crossmatch is the other route, where the blood bank is accredited to use it.
Why it matters
An ABO error ranks among the most dangerous events in transfusion. A missed antibody can cause a hemolytic reaction days later. In emergency and transport care, the sample and the unit tag are what connect the patient to the blood bank.
Clinical Pearls
Draw it first. Draw the type and screen from the first IV or IO, before any blood goes in. Once transfusion starts, the sample can carry donor cells and muddy the testing.
Two identifiers at the bedside. Check the armband, the sample label and the unit tag against each other before every unit. ABO errors drive the worst acute hemolytic reactions.
Uncrossmatched O is a bridge. Reach for it only when delay would be fatal. Move to matched blood as soon as results return. Keep a running count of units for the blood bank.
Delayed reactions come later. The reaction can show up days to weeks after transfusion. Watch for unexplained fever, a positive DAT or a falling hemoglobin. Tell patients who leave after transfusion what to report.
Transport tip. Send the sample and the unit tags with the patient. Ask the receiving blood bank early whether it wants a new sample. Every facility sets its own acceptance rules.
Nursing monitoring. Start each unit slowly and watch it closely. Check vital signs at the start and at intervals per policy. Stop the unit for fever, rash, dyspnea, hypotension or dark urine.
New antibodies can appear. A negative screen can turn positive later. Recent transfusion, pregnancy or chronic transfusion can create an antibody. Retest after any new exposure.
References
- AABB. Circular of Information for the Use of Human Blood and Blood Components (June 2024). Includes the transfusion compatibility, emergency-use and delayed hemolytic reaction sections used on this page. https://www.aabb.org/news-resources/resources/circular-of-information
- Carson JL, et al. Red blood cell transfusion: 2023 AABB International Guidelines. JAMA. 2023;330(19):1892–1902. https://doi.org/10.1001/jama.2023.12914
- Morgan KM, Abou Khalil E, Feeney EV, et al. The Efficacy of Low-Titer Group O Whole Blood Compared With Component Therapy in Civilian Trauma Patients: A Meta-Analysis. Crit Care Med. 2024;52(7):e390–e404. https://doi.org/10.1097/CCM.0000000000006244
- Williams J, Merutka N, Meyer D, et al. Safety profile and impact of low-titer group O whole blood for emergency use in trauma. J Trauma Acute Care Surg. 2020;88(1):87–93 (online 2019). https://doi.org/10.1097/TA.0000000000002498
- Henry R, Coleman JR, Holcomb JB, et al. Post-Transfusion Management of RhD-Negative Females of Childbearing Potential Who Receive RhD-Positive Low-Titer Group O Whole Blood and Red Blood Cells During Trauma Resuscitation: A Joint Position Statement and Resource Document of the American College of Surgeons Committee on Trauma and partners. J Am Coll Surg. 2026. https://doi.org/10.1097/XCS.0000000000002099
- Yazer MH, Dunbar NM, Delaney M; BEST Collaborative. Survey of the RhD selection and issuing practices for uncrossmatched blood products at pediatric trauma hospitals in the United States. Transfusion. 2021;61(12):3328–3334. https://doi.org/10.1111/trf.16692
Medical Disclaimer
- For Educational Purposes Only: This content is intended for educational reference and should not be used for clinical decision-making.
- Not a Substitute for Professional Judgment: Always consult your local protocols, institutional guidelines, and supervising physicians.
- Verify Before Acting: Users are responsible for verifying information through authoritative sources before any clinical application.
AI Assistance Notice
AI was used to assist in organizing, paraphrasing, and formatting this information.